Mass Balance and Pharmacokinetics of [(14)C]Telavancin following Intravenous Administration to Healthy Male Volunteers

Por Shaw, Jeng-Pyng, Cheong, Jonathan, Goldberg, Michael R., Kitt, Michael M.
Publicado em 2010

Intrapulmonary Distribution of Intravenous Telavancin in Healthy Subjects and Effect of Pulmonary Surfactant on In Vitro Activities of Telavancin and Other Antibiotics

Por Gotfried, Mark H., Shaw, Jeng-Pyng, Benton, Bret M., Krause, Kevin M., Goldberg, Michael R., Kitt, Michael M., Barriere, Steven L.
Publicado em 2008

Effects of TD-5108 on Gastrointestinal Transit and Bowel Function in Health and Pharmacokinetics in Health and Constipation

Por Manini, Mhd Louai, Camilleri, Michael, Goldberg, Michael, Sweetser, Seth, McKinzie, Sanna, Burton, Duane, Wong, Shekman, Kitt, Michael M., Li, Yu-Ping, Zinsmeister, Alan R.
Publicado em 2009

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study

Por Stryjewski, Martin E, Lentnek, Arnold, O’Riordan, William, Pullman, John, Tambyah, Paul Anantharajah, Miró, Jose M, Fowler Jr, Vance G, Barriere, Steven L, Kitt, Michael M, Corey, G Ralph
Publicado em 2014

Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa

Por Siegal, Deborah, Lu, Genmin, Leeds, Janet M., Karbarz, Mark, Castillo, Janice, Mathur, Vandana, Hutchaleelaha, Athiwat, Sinha, Uma, Kitt, Michael, McClure, Matt, Hollenbach, Stanley J., Curnutte, John T., Conley, Pamela B., Crowther, Mark
Publicado no Blood Adv (2017)

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

Por Stryjewski, Martin E., Chu, Vivian H., O'Riordan, William D., Warren, Brian L., Dunbar, Lala M., Young, David M., Vallée, Marc, Fowler, Vance G., Morganroth, Joel, Barriere, Steven L., Kitt, Michael M., Corey, G. Ralph
Publicado em 2006

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens

Por Rubinstein, Ethan, Lalani, Tahaniyat, Corey, G. Ralph, Kanafani, Zeina A., Nannini, Esteban C., Rocha, Marcelo G., Rahav, Galia, Niederman, Michael S., Kollef, Marin H., Shorr, Andrew F., Lee, Patrick C., Lentnek, Arnold L., Luna, Carlos M., Fagon, Jean-Yves, Torres, Antoni, Kitt, Michael M., Genter, Fredric C., Barriere, Steven L., Friedland, H. David, Stryjewski, Martin E.
Publicado em 2011